Reata's bar­dox­olone of­fers promise in pa­tients with rare kid­ney dis­or­der

Af­ter sur­pris­ing Wall Street with pos­i­tive da­ta on its drug, omavelox­olone, in pa­tients suf­fer­ing from a no­to­ri­ous­ly hard-to-treat de­gen­er­a­tive neu­ro­mus­cu­lar dis­or­der last month, Rea­ta Phar­ma on Mon­day un­veiled piv­otal re­sults from a tri­al test­ing an­oth­er drug, bar­dox­olone, in pa­tients with a rare, ge­net­ic form of chron­ic kid­ney dis­ease for which there ex­ist no ap­proved ther­a­pies.

Bar­dox­olone, like Rea­ta’s oth­er lead drug — omavelox­olone — is a small mol­e­cule en­gi­neered to bind to a gene called Keap1 to en­hance the ac­tiv­i­ty of the pro­tein Nrf2 in or­der to defuse in­flam­ma­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.